probucol has been researched along with Acute Confusional Senile Dementia in 10 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These results are consistent with recent reports suggesting that the long term use of cholesterol lowering drugs that block 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) activity in the fourth and fifth decade of life may help reduce the risk of developing AD at later age." | 2.43 | Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. ( Poirier, J, 2005) |
| "The pathogenesis of Alzheimer's disease (AD) is characterized by overproduction, impaired clearance, and deposition of amyloid-β peptides (Aβ) and connected to cholesterol homeostasis." | 1.51 | Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells. ( Agujetas, VR; Albrecher, NM; Carmen Kober, A; Colell, A; de Dios, C; Fanaee-Danesh, E; Gali, CC; Madeo, F; Malle, E; Manavalan, APC; Panzenboeck, U; Reiter, M; Stracke, A; Sun, Y; Tadic, J; Tam-Amersdorfer, C; Zandl-Lang, M, 2019) |
| "Probucol treatment significantly protected against the behavioral and hippocampal biochemical changes induced by STZ." | 1.42 | Probucol mitigates streptozotocin-induced cognitive and biochemical changes in mice. ( Colle, D; de Bem, AF; de Oliveira, J; Dos Santos, AA; Farina, M; Hort, MA; Moreira, ELG; Peres, KC; Ribeiro, RP; Santos, DB, 2015) |
| "Mice treated with Probucol had the drug incorporated into the chow at 1% (w/w)." | 1.38 | Probucol suppresses enterocytic accumulation of amyloid-β induced by saturated fat and cholesterol feeding. ( Dhaliwal, S; Galloway, S; Mamo, JC; Pallebage-Gamarallage, MM; Takechi, R, 2012) |
| "Probucol is a non-Statin cholesterol-lowering drug and a potent inducer of apolipoprotein E (apoE) production in peripheral circulation." | 1.32 | The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease. ( Champagne, D; Dea, D; Pearson, D; Poirier, J; Rochford, J, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lam, V | 1 |
| Clarnette, R | 1 |
| Francis, R | 1 |
| Bynevelt, M | 1 |
| Watts, G | 1 |
| Flicker, L | 1 |
| Orr, CF | 1 |
| Loh, P | 1 |
| Lautenschlager, N | 1 |
| Reid, CM | 1 |
| Foster, JK | 1 |
| Dhaliwal, SS | 1 |
| Robinson, S | 1 |
| Corti, E | 1 |
| Vaccarezza, M | 1 |
| Horgan, B | 1 |
| Takechi, R | 2 |
| Mamo, J | 1 |
| Gamit, N | 1 |
| Patil, M | 1 |
| B Sundrappa, S | 1 |
| Sundaram, SM | 1 |
| Sethi, G | 1 |
| Dharmarajan, A | 1 |
| Warrier, S | 1 |
| Ihara, M | 1 |
| Saito, S | 1 |
| Fanaee-Danesh, E | 1 |
| Gali, CC | 1 |
| Tadic, J | 1 |
| Zandl-Lang, M | 1 |
| Carmen Kober, A | 1 |
| Agujetas, VR | 1 |
| de Dios, C | 1 |
| Tam-Amersdorfer, C | 1 |
| Stracke, A | 1 |
| Albrecher, NM | 1 |
| Manavalan, APC | 1 |
| Reiter, M | 1 |
| Sun, Y | 1 |
| Colell, A | 1 |
| Madeo, F | 1 |
| Malle, E | 1 |
| Panzenboeck, U | 1 |
| Gan, X | 1 |
| Huang, S | 1 |
| Wu, L | 1 |
| Wang, Y | 1 |
| Hu, G | 1 |
| Li, G | 1 |
| Zhang, H | 1 |
| Yu, H | 1 |
| Swerdlow, RH | 1 |
| Chen, JX | 1 |
| Yan, SS | 1 |
| Poirier, J | 3 |
| Miron, J | 1 |
| Picard, C | 1 |
| Gormley, P | 1 |
| Théroux, L | 1 |
| Breitner, J | 1 |
| Dea, D | 2 |
| Santos, DB | 1 |
| Colle, D | 1 |
| Moreira, ELG | 1 |
| Peres, KC | 1 |
| Ribeiro, RP | 1 |
| Dos Santos, AA | 1 |
| de Oliveira, J | 1 |
| Hort, MA | 1 |
| de Bem, AF | 1 |
| Farina, M | 1 |
| Pallebage-Gamarallage, MM | 1 |
| Galloway, S | 1 |
| Dhaliwal, S | 1 |
| Mamo, JC | 1 |
| Champagne, D | 1 |
| Pearson, D | 1 |
| Rochford, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ProdromeNeuro: An Open-Label Study of Omega 3 Oil Nutritional Supplementation for Aging-Related Cognitive Decline[NCT04484454] | 20 participants (Actual) | Interventional | 2020-07-17 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for probucol and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease.
Topics: Alleles; Alzheimer Disease; Amyloid beta-Peptides; Anticholesteremic Agents; Apolipoprotein E4; Apol | 2014 |
Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease.
Topics: Alzheimer Disease; Anticholesteremic Agents; Apolipoproteins E; Biological Transport; Brain; Cholest | 2005 |
1 trial available for probucol and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study).
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Australia; Clinical Trials, Phase II as Topic; Co | 2022 |
7 other studies available for probucol and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Mesenchymal stem cell-derived rapid drug screening system for Alzheimer's disease for the identification of novel drugs.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Drug | 2023 |
[Drug Repositioning for Alzheimer's Disease].
Topics: Alzheimer Disease; Cilostazol; Dabigatran; Drug Repositioning; Humans; Insulin; Probucol; Telmisarta | 2019 |
Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells.
Topics: ADAM10 Protein; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Anim | 2019 |
Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antioxidants; Dynamins; Extracellular Signal-Regulated M | 2014 |
Probucol mitigates streptozotocin-induced cognitive and biochemical changes in mice.
Topics: Acetylcholinesterase; Administration, Oral; Alzheimer Disease; Amyloid Precursor Protein Secretases; | 2015 |
Probucol suppresses enterocytic accumulation of amyloid-β induced by saturated fat and cholesterol feeding.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloidosis; Animals; Anticholesteremic Agents; Apolipopro | 2012 |
The cholesterol-lowering drug probucol increases apolipoprotein E production in the hippocampus of aged rats: implications for Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Animals; Apolipoproteins E; Cholesterol; Hippocampus; Male; Probucol; Rats | 2003 |